Northern Trust Corp Has $82.44 Million Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Northern Trust Corp raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 13.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 248,142 shares of the company's stock after purchasing an additional 28,968 shares during the period. Northern Trust Corp owned about 0.80% of Medpace worth $82,440,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Lindbrook Capital LLC boosted its stake in Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after acquiring an additional 29 shares during the last quarter. HBK Sorce Advisory LLC lifted its position in shares of Medpace by 0.5% during the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock worth $1,789,000 after purchasing an additional 29 shares during the last quarter. Assetmark Inc. grew its stake in Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after purchasing an additional 29 shares in the last quarter. Proficio Capital Partners LLC increased its holdings in Medpace by 4.1% in the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock valued at $243,000 after buying an additional 29 shares during the last quarter. Finally, Schulhoff & Co. Inc. raised its stake in Medpace by 1.2% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock valued at $874,000 after buying an additional 30 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Down 1.6 %

Medpace stock traded down $4.78 during mid-day trading on Friday, hitting $296.03. 199,914 shares of the company's stock traded hands, compared to its average volume of 346,768. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $459.77. The company has a market cap of $8.51 billion, a PE ratio of 23.44, a price-to-earnings-growth ratio of 3.81 and a beta of 1.55. The firm has a 50 day moving average price of $306.90 and a 200 day moving average price of $328.58.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $3.06 by $0.61. The business had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same quarter in the prior year, the company posted $3.20 earnings per share. On average, analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction dated Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the transaction, the director now directly owns 2,998 shares of the company's stock, valued at $904,856.36. The trade was a 36.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 20.30% of the company's stock.

Analyst Upgrades and Downgrades

MEDP has been the subject of a number of research analyst reports. Robert W. Baird lowered their price target on Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. William Blair reiterated a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. Truist Financial reduced their price target on shares of Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research report on Wednesday, April 23rd. Leerink Partners started coverage on shares of Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective for the company. Finally, TD Cowen cut shares of Medpace from a "buy" rating to a "hold" rating and cut their target price for the stock from $370.00 to $328.00 in a report on Monday, April 14th. Eleven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $349.30.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.